Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System
Edwards Lifesciences Corporation (EW)
Last edwards lifesciences corporation earnings: 4/23 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.edwards.com
Company Research
Source: Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement therapy using a transfemoral approach to treat MR.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250414835786/en/Edwards' SAPIEN M3 Transcatheter Mitral Valve Replacement System“Edwards’ 65-year legacy of structural heart innovation is firmly rooted in transforming care for underserved patient populations and the SAPIEN M3 system is built on the proven SAPIEN platform, which has been used in more than 8,000 procedures in the mitral po
Show less
Read more
Impact Snapshot
Event Time:
EW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EW alerts
High impacting Edwards Lifesciences Corporation news events
Weekly update
A roundup of the hottest topics
EW
News
- Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board [Yahoo! Finance]Yahoo! Finance
- Edwards Lifesciences (NYSE:EW) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $90.00.MarketBeat
- Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider [Yahoo! Finance]Yahoo! Finance
EW
Earnings
- 10/30/25 - Beat
EW
Sec Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- EW's page on the SEC website